C4 Therapeutics Inc. Common Stock (CCCC)
Stock · NASDAQ · Health Care
$3.85as of 8/28/2026
Price chart
Open in TradingViewActive signals
No technical signal is currently active for this symbol.
Support level
$2.73
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Fundamentals
- Market cap
- $402.46M
- P/E (trailing)
- —
- P/E (forward)
- —
- EPS (trailing)
- —
- Dividend yield
- —
- Beta
- —
- Avg. volume
- —
How C4 Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
C4 Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- CCCCC4 Therapeutics Inc. Common Stock$3.85▼ 6.10%Market cap $402.46MP/E —
- STROSutro Biopharma Inc. Common Stock$20.42▼ 4.18%Market cap $400.18MP/E —$7.15$43.85
- XFORX4 Pharmaceuticals Inc. Common Stock$4.05▼ 4.26%Market cap $393.31MP/E 3.24$2.8$4.83
- OCGNOcugen Inc. Common Stock$1.32▼ 3.65%Market cap $420.50MP/E —$1$2.73
- FENCFennec Pharmaceuticals Inc. Common Stock$12.19▲ 3.57%Market cap $378.17MP/E —$5.65$13.25
- PALIPalisade Bio Inc. Common Stock$2.01▼ 4.74%Market cap $362.78MP/E —$0.53$2.86
- LXEOLexeo Therapeutics Inc. Common Stock$4.87▼ 2.51%Market cap $357.27MP/E —$3.99$10.99
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CCCC C4 Therapeutics Inc. Common Stock | $402.46M | — | $3.85 | ▼ 6.10% | |
| STRO Sutro Biopharma Inc. Common Stock | $400.18M | — | $20.42 | ▼ 4.18% | $7.15$43.85 |
| XFOR X4 Pharmaceuticals Inc. Common Stock | $393.31M | 3.24 | $4.05 | ▼ 4.26% | $2.8$4.83 |
| OCGN Ocugen Inc. Common Stock | $420.50M | — | $1.32 | ▼ 3.65% | $1$2.73 |
| FENC Fennec Pharmaceuticals Inc. Common Stock | $378.17M | — | $12.19 | ▲ 3.57% | $5.65$13.25 |
| PALI Palisade Bio Inc. Common Stock | $362.78M | — | $2.01 | ▼ 4.74% | $0.53$2.86 |
| LXEO Lexeo Therapeutics Inc. Common Stock | $357.27M | — | $4.87 | ▼ 2.51% | $3.99$10.99 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue EstimatesYahoo · 8/11/2026
- C4 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business HighlightsYahoo · 8/11/2026
- C4 Therapeutics Q2 EPS $(0.18) Beats $(0.23) Estimate, Sales $6.641M Beat $4.000M EstimateBenzinga · 8/11/2026
- C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Yahoo · 8/10/2026
Insider Activity
Insider Actions →Acquired
528.0K
Disposed
7.4K
- Leonard Reyno · July 10, 2026 · Tax Withholding7.4K @ $4.06
- Leonard Reyno · July 10, 2026 · Option Exercise15.3K
- Donna Roy Grogan · July 1, 2026 · Grant3.3K @ $4.34
- Kenneth Carl Anderson · July 1, 2026 · Grant2.6K @ $4.34
- Koppikar Utpal · June 24, 2026 · Grant62.0K
- Kenneth Carl Anderson · June 24, 2026 · Grant62.0K
- Ronald Harold Wilfred Cooper · June 24, 2026 · Grant62.0K
- Bessen Laura · June 24, 2026 · Grant62.0K
- Fawell Stephen · June 24, 2026 · Grant62.0K
- Donna Roy Grogan · June 24, 2026 · Grant62.0K
- Hughes Owen · June 24, 2026 · Grant62.0K
- Hoerter Steven L. · June 24, 2026 · Grant62.0K
- Kenneth Carl Anderson · June 1, 2026 · Option Exercise1.1K @ $2.11
- Kenneth Carl Anderson · April 1, 2026 · Grant4.3K @ $2.7
- Donna Roy Grogan · April 1, 2026 · Grant5.4K @ $2.7
Institutional Ownership
March 31, 2026
- Total shares held
- 80.99M
- Total value held
- $207.41M
- Institutional holders
- 119
Top holders this quarter
- Unknown9.07M
- Unknown8.00M
- Unknown7.17M
- Unknown7.00M
- Unknown3.86M
- Unknown3.80M
- Unknown3.04M
- Unknown2.96M
- Unknown2.59M
- Unknown2.46M
See the full, filterable feed with live charts on the MarketWall dashboard.